Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab or Lapatinib in Oesophagogastric Adenocarcinoma
NCT00450203Phase 3Unknown
- Start
- Oct 2007
- Primary completion
- Dec 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, lapatinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC). Status: unknown.
02
Drugs
bevacizumablapatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00450203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450203.